Health
0
IC 100 reduces inflammasome activation, alpha-synuclein clumps - Parkinson's News Today
ZyVersa Therapeutics is preparing proof-of-concept studies in animal models to test IC 100 as a disease-modifying therapy for Parkinson’s.
Comments